FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

g,									

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden

hours per response:

0.5

ì	Check this box if no longer subject to							
	Section 16. Form 4 or Form 5							
J	obligations may continue. See							
	Instruction 1(b).							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Gould Robert J					2. Issuer Name and Ticker or Trading Symbol Fulcrum Therapeutics, Inc. [FULC]						(Che	Relationship of Reporting Person(s) to (Check all applicable) X Director 109			
(Last) (First) (Middle) C/O FULCRUM THERAPEUTICS, INC. 26 LANDSDOWNE STREET					3. Date of Earliest Transaction (Month/Day/Year) 01/23/2020						X Officer (give title below) Other (specify below) President & CEO				
(Street) CAMBRIDGE MA 02139 (City) (State) (Zip)				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line	dividual or Joint/Group Filing (Check Applicable) K Form filed by One Reporting Person Form filed by More than One Reporting Person				
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned														
1. Title of Security (Instr. 3) 2. Transa Date (Month/D				9	Execution Day/Year) if any		A. Deemed Execution Date, f any Month/Day/Year)		Code (Instr.			5. Amoun Securities Beneficia Owned Fo Reported	Following (I)	rm: Direct I or Indirect I (Instr. 4) (7. Nature of ndirect Beneficial Ownership
								Code V	Amount	(A) o (D)	r Price	Transacti (Instr. 3 a	on(s)		Instr. 4)
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code (5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)		
Stock Option (right to buy)	\$16.87	01/23/2020		A		200,000		(1)	01/22/2030	Common Stock	200,000	\$0.00	200,000	D	

Explanation of Responses:

1. This option was granted on January 23, 2020 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2020, subject to continued service.

Remarks:

<u>/s/ Peter Thomson, as attorney-</u>in-fact for Robert Gould

01/27/2020

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.